Form 4: Vistagen Therapeutics CFO Granted 100,000 Stock Options

Vistagen Therapeutics, Inc. Chief Financial Officer, Cynthia Lynn Anderson, was granted 100,000 stock options with an exercise price of $1.96, vesting over three years.

Summary

• Cynthia Lynn Anderson, the Chief Financial Officer of Vistagen Therapeutics, Inc. (VTGN), was granted 100,000 stock options.
• The stock options have an exercise price of $1.96 per share.
• Vesting for these options will commence on June 23, 2025 (the Grant Date), and will occur in equal monthly installments over a three-year period.
• The options are scheduled to become fully vested on the three-year anniversary of the Grant Date, which is June 23, 2028.
• The expiration date for these stock options is June 23, 2035.
• This grant was made pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options to a key executive is a standard practice that aligns management incentives with shareholder value, indicating stability in executive compensation strategy.

Positives

• The grant of stock options to a key executive like the CFO aligns her long-term incentives with the company's performance and shareholder value.
• The three-year vesting schedule encourages executive retention and sustained focus on long-term company growth.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, which is a standard aspect of equity compensation plans.

Future Outlook

The stock options granted to the CFO are scheduled to vest in equal monthly installments over a three-year period, starting June 23, 2025, and fully vesting by June 23, 2028. The options will expire on June 23, 2035.

Industry Context

The grant of stock options to key executives is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors, to attract, retain, and incentivize talent by aligning their financial interests with the long-term success of the company.

Related Party Transactions

• Grant of 100,000 stock options to Cynthia Lynn Anderson, the Chief Financial Officer, as part of her compensation package under the company's equity incentive plan. This is a standard related-party transaction for executive compensation.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through aligned executive incentives, balanced against potential future dilution from option exercise.
• Employees: Reinforces the company's commitment to equity-based compensation, which can be a positive for attracting and retaining talent.

Next Steps

• Continued vesting of the 100,000 stock options over the next three years until June 23, 2028.
• Potential exercise of the vested options by Cynthia Lynn Anderson at or after the vesting dates, up to the expiration date of June 23, 2035.

Key Dates

Recommendation

Keywords

Vistagen Therapeutics, VTGN, Stock Options, Equity Compensation, CFO, Cynthia Lynn Anderson, SEC Form 4, Insider Transaction